Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Deveson Lucas D, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00425-19. doi: 10.1128/AAC.00425-19. Print 2019 Jul.

PMID:
30988147
2.

A Cohort Study of the Impact of Carbapenem-Resistant Enterobacteriaceae Infections on Mortality of Patients Presenting with Sepsis.

Sabino S, Soares S, Ramos F, Moretti M, Zavascki AP, Rigatto MH.

mSphere. 2019 Apr 10;4(2). pii: e00052-19. doi: 10.1128/mSphere.00052-19.

3.

Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity.

Nation RL, Rigatto MHP, Falci DR, Zavascki AP.

Antibiotics (Basel). 2019 Mar 14;8(1). pii: E24. doi: 10.3390/antibiotics8010024. Review.

4.

Detection of Enterobacterales resistant to polymyxins using Rapid Polymyxins NP test.

Dalmolin TV, Dias GÁ, de Castro LP, Ávila H, Magagnin CM, Zavascki AP, de Lima-Morales D, Barth AL.

Braz J Microbiol. 2019 Apr;50(2):425-428. doi: 10.1007/s42770-019-00053-x. Epub 2019 Mar 11.

PMID:
30859495
5.

Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.

Medeiros GS, Rigatto MH, Falci DR, Zavascki AP.

Int J Antimicrob Agents. 2019 Feb;53(2):152-157. doi: 10.1016/j.ijantimicag.2018.10.010. Epub 2018 Oct 26.

PMID:
30722960
6.
7.

Dissemination of blaOXA-370 is mediated by IncX plasmids and the Tn6435 transposon.

Magagnin CM, Campos JC, da Rocha DA, Sampaio SCF, Rozáles FP, Barth AL, Zavascki AP, Sampaio JLM.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2165-2169. doi: 10.1007/s10096-018-3356-x. Epub 2018 Aug 21.

PMID:
30128668
8.

KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?

Antochevis LC, Magagnin CM, Nunes AG, Goulart TM, Martins AS, Cayô R, Gales AC, Barth AL, Zavascki AP.

J Glob Antimicrob Resist. 2018 Dec;15:173-177. doi: 10.1016/j.jgar.2018.07.011. Epub 2018 Jul 30.

PMID:
30071353
9.

Rapid Detection of Carbapenemase Production Directly from Blood Culture by Colorimetric Methods: Evaluation in a Routine Microbiology Laboratory.

Lima-Morales D, Ávila H, Soldi T, Dalmolin TV, Lutz L, Aquino V, Zavascki AP, Barth AL.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00325-18. doi: 10.1128/JCM.00325-18. Print 2018 Sep.

10.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
11.

Colistin versus colistin plus meropenem for severe infections.

Zavascki AP.

Lancet Infect Dis. 2018 May;18(5):493-494. doi: 10.1016/S1473-3099(18)30212-3. No abstract available.

PMID:
29695356
12.

Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.

Gomes EC, Falci DR, Bergo P, Zavascki AP, Rigatto MH.

Int J Antimicrob Agents. 2018 Jul;52(1):86-89. doi: 10.1016/j.ijantimicag.2018.02.016. Epub 2018 Mar 2.

PMID:
29501603
13.

Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis.

Abboud CS, Rao GG, Souza EE, Zavascki AP, Kiffer C.

Braz J Infect Dis. 2018 Jan - Feb;22(1):51-54. doi: 10.1016/j.bjid.2017.10.006. Epub 2017 Nov 26.

14.

Acquisition of the mcr-1 gene by a high-risk clone of KPC-2-producing Klebsiella pneumoniae ST437/CC258, Brazil.

Dalmolin TV, Martins AF, Zavascki AP, de Lima-Morales D, Barth AL.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):132-133. doi: 10.1016/j.diagmicrobio.2017.09.016. Epub 2017 Oct 5.

15.

Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy.

Zavascki AP, Girardello R, Magagnin CM, Antochevis LC, Maciel RA, Palmeiro JK, Gales AC.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):134-138. doi: 10.1016/j.diagmicrobio.2017.10.006. Epub 2017 Oct 19.

PMID:
29150371
16.

Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.

John JF, Falci DR, Rigatto MH, Oliveira RD, Kremer TG, Zavascki AP.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01617-17. doi: 10.1128/AAC.01617-17. Print 2018 Jan.

17.

Characteristics of Enterobacteriaceae Isolates Coharboring Distinct Carbapenemase Genes.

Rozales FP, Lovison OA, Magagnin CM, Martins AS, Crispim MN, Zavascki AP, Barth AL.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1123-1126. doi: 10.1017/ice.2017.146. Epub 2017 Jul 20. No abstract available.

PMID:
28724459
18.

Dissemination of bla OXA-370 gene among several Enterobacteriaceae species in Brazil.

Magagnin CM, Rozales FP, Antochevis L, Nunes LS, Martins AS, Barth AL, Sampaio JM, Zavascki AP.

Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1907-1910. doi: 10.1007/s10096-017-3012-x. Epub 2017 May 30.

PMID:
28555403
19.

Co-occurrence of mcr-1 and blaKPC-2 in a clinical isolate of Escherichia coli in Brazil.

Dalmolin TV, Castro L, Mayer FQ, Zavascki AP, Martins AF, Lima-Morales D, Barth AL.

J Antimicrob Chemother. 2017 Aug 1;72(8):2404-2406. doi: 10.1093/jac/dkx142. No abstract available.

PMID:
28505353
20.

Detection of OXA-370 directly from rectal swabs and blood culture vials using an immunochromatographic assay.

Nodari CS, Gales AC, Barth AL, Magagnin CM, Zavascki AP, Carvalhaes CG.

J Microbiol Methods. 2017 Aug;139:92-94. doi: 10.1016/j.mimet.2017.05.003. Epub 2017 May 5.

PMID:
28483549
21.

Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.

Zavascki AP, Klee BO, Bulitta JB.

Expert Rev Anti Infect Ther. 2017 Jun;15(6):519-526. doi: 10.1080/14787210.2017.1316193. Epub 2017 Apr 17. Review.

PMID:
28375030
22.

Characterization of Transformants Obtained From NDM-1-Producing Enterobacteriaceae in Brazil.

Rozales FP, Magagnin CM, Campos JC, Pagano M, Nunes LS, Pancotto LR, Sampaio JLM, Zavascki AP, Barth AL.

Infect Control Hosp Epidemiol. 2017 May;38(5):634-636. doi: 10.1017/ice.2017.28. Epub 2017 Mar 7. No abstract available.

PMID:
28264751
23.

Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?

Zavascki AP, Nation RL.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02319-16. doi: 10.1128/AAC.02319-16. Print 2017 Mar. Review.

24.

Low doses of colistimethate: Don't rush in!

Zavascki AP, Nation RL.

Clin Infect Dis. 2017 Mar 1;64(5):695-696. Epub 2016 Dec 16. No abstract available.

PMID:
27986687
25.

Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.

Zavascki AP, Schuster LF, Duquia RP.

Int J Antimicrob Agents. 2016 Nov;48(5):579-580. doi: 10.1016/j.ijantimicag.2016.08.010. Epub 2016 Sep 30. No abstract available.

PMID:
27720305
26.

Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil.

Bartolleti F, Seco BM, Capuzzo Dos Santos C, Felipe CB, Lemo ME, Alves Tda S, Passadore LF, Mimica MJ, Sampaio SC, Zavascki AP, Sampaio JL.

Emerg Infect Dis. 2016 Oct;22(10):1849-51. doi: 10.3201/eid2210.160695. No abstract available.

27.

Letter to the editor: Escherichia coli harbouring mcr-1 gene isolated from poultry not exposed to polymyxins in Brazil.

Lentz SA, de Lima-Morales D, Cuppertino VM, Nunes Lde S, da Motta AS, Zavascki AP, Barth AL, Martins AF.

Euro Surveill. 2016 Jun 30;21(26). doi: 10.2807/1560-7917.ES.2016.21.26.30267. No abstract available. Erratum in: Euro Surveill. 2016 Aug 4;21(31):.

28.

Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.

Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2443-9. doi: 10.1128/AAC.02634-15. Print 2016 Apr.

29.

Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B.

Rigatto MH, Falci DR, Lopes NT, Zavascki AP.

Int J Antimicrob Agents. 2016 Feb;47(2):146-50. doi: 10.1016/j.ijantimicag.2015.11.007. Epub 2015 Dec 11.

PMID:
26742727
30.

Brazil's Family Health Strategy.

Zavascki AP.

N Engl J Med. 2015 Sep 24;373(13):1277-8. doi: 10.1056/NEJMc1509056. No abstract available.

PMID:
26398089
31.

Characterization of Tn3000, a Transposon Responsible for blaNDM-1 Dissemination among Enterobacteriaceae in Brazil, Nepal, Morocco, and India.

Campos JC, da Silva MJ, dos Santos PR, Barros EM, Pereira Mde O, Seco BM, Magagnin CM, Leiroz LK, de Oliveira TG, de Faria-Júnior C, Cerdeira LT, Barth AL, Sampaio SC, Zavascki AP, Poirel L, Sampaio JL.

Antimicrob Agents Chemother. 2015 Dec;59(12):7387-95. doi: 10.1128/AAC.01458-15. Epub 2015 Sep 21.

32.

The changing epidemiology of Acinetobacter spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report.

Vasconcelos AT, Barth AL, Zavascki AP, Gales AC, Levin AS, Lucarevschi BR, Cabral BG, Brasiliense DM, Rossi F, Furtado GH, Carneiro IC, da Silva JO, Ribeiro J, Lima KV, Correa L, Britto MH, Silva MT, da Conceição ML, Moreira M, Martino MD, de Freitas MR, Oliveira MS, Dalben MF, Guzman RD, Cayô R, Morais R, Santos SA, Martins WM.

Diagn Microbiol Infect Dis. 2015 Dec;83(4):382-5. doi: 10.1016/j.diagmicrobio.2015.08.006. Epub 2015 Aug 12.

PMID:
26364001
33.

Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.

Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP.

Antimicrob Agents Chemother. 2015 Oct;59(10):6575-80. doi: 10.1128/AAC.00494-15. Epub 2015 Aug 10.

34.

Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.

Zavascki AP, Manfro RC, Maciel RA, Falci DR.

Ann Pharmacother. 2015 Oct;49(10):1171-2. doi: 10.1177/1060028015595643. Epub 2015 Jul 17. No abstract available.

PMID:
26187742
35.

Lactobacillus rhamnosus bacteremia in a kidney transplant recipient.

Falci DR, Rigatto MH, Cantarelli VV, Zavascki AP.

Transpl Infect Dis. 2015 Aug;17(4):610-2. doi: 10.1111/tid.12410. Epub 2015 Jul 14.

PMID:
26061146
36.

Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.

Toledo PV, Aranha Junior AA, Arend LN, Ribeiro V, Zavascki AP, Tuon FF.

Antimicrob Agents Chemother. 2015 Jul;59(7):4301-4. doi: 10.1128/AAC.00323-15. Epub 2015 Apr 20.

37.

In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.

Barth N, Ribeiro VB, Zavascki AP.

Antimicrob Agents Chemother. 2015;59(6):3596-7. doi: 10.1128/AAC.00365-15. Epub 2015 Mar 23.

38.

High endemic rates of OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates caused by the persistence of major clones in hospitals in a Brazilian city 5 years after an outbreak.

Pagano M, Barin J, Martins AF, Zavascki AP.

Infect Control Hosp Epidemiol. 2015 Jul;36(7):860-2. doi: 10.1017/ice.2015.52. Epub 2015 Mar 16. No abstract available.

PMID:
25773462
39.

Streptococcus pneumoniae appendicitis in an adult patient.

Caierão J, Cornely AF, da Cunha GR, Mott M, Zavascki AP, Dias C.

Am J Emerg Med. 2015 Jul;33(7):990.e1-3. doi: 10.1016/j.ajem.2014.12.051. Epub 2014 Dec 30.

PMID:
25676850
40.

Emergence of NDM-1-producing Acinetobacter pittii in Brazil.

Pagano M, Poirel L, Martins AF, Rozales FP, Zavascki AP, Barth AL, Nordmann P.

Int J Antimicrob Agents. 2015 Apr;45(4):444-5. doi: 10.1016/j.ijantimicag.2014.12.011. Epub 2015 Jan 12. No abstract available.

PMID:
25616530
41.

Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.

Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP.

J Antimicrob Chemother. 2015 May;70(5):1552-7. doi: 10.1093/jac/dku561. Epub 2015 Jan 20.

PMID:
25604744
42.

Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil.

Rozales FP, Ribeiro VB, Magagnin CM, Pagano M, Lutz L, Falci DR, Machado A, Barth AL, Zavascki AP.

Int J Infect Dis. 2014 Aug;25:79-81. doi: 10.1016/j.ijid.2014.01.005. Epub 2014 May 21.

43.

Heteroresistance to carbapenems in New Delhi metallo-β-lactamase-1-producing isolates: a challenge for detection?

Zavascki AP, Falci DR, da Silva RC, Dalarosa MG, Ribeiro VB, Rozales FP, Luz DI, Magagnin CM, Vieira FJ, Sampaio JM, Barth AL.

Infect Control Hosp Epidemiol. 2014 Jun;35(6):751-2. doi: 10.1086/676442. No abstract available.

PMID:
24799663
44.

Performance of quantification of Modified Hodge Test: an evaluation with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae isolates.

Ribeiro VB, Linhares AR, Zavascki AP, Barth AL.

Biomed Res Int. 2014;2014:139305. doi: 10.1155/2014/139305. Epub 2014 Mar 26.

45.

Detection of OXA-370, an OXA-48-related class D β-lactamase, in Enterobacter hormaechei from Brazil.

Sampaio JL, Ribeiro VB, Campos JC, Rozales FP, Magagnin CM, Falci DR, da Silva RC, Dalarosa MG, Luz DI, Vieira FJ, Antochevis LC, Barth AL, Zavascki AP.

Antimicrob Agents Chemother. 2014 Jun;58(6):3566-7. doi: 10.1128/AAC.02510-13. Epub 2014 Apr 7. No abstract available.

46.

Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.

Zavascki AP.

Expert Rev Anti Infect Ther. 2014 May;12(5):531-3. doi: 10.1586/14787210.2014.902307. Epub 2014 Mar 25.

PMID:
24666285
47.

Carbapenem-resistant GES-5-producing Klebsiella pneumoniae in Southern Brazil.

Ribeiro VB, Falci DR, Rozales FP, Barth AL, Zavascki AP.

Braz J Infect Dis. 2014 Mar-Apr;18(2):231-2. doi: 10.1016/j.bjid.2013.12.002. Epub 2014 Feb 8. No abstract available.

48.

Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.

Alves MD, Ribeiro VB, Tessari JP, Mattiello F, De Bacco G, Luz DI, Vieira FJ, Behle TF, Pasqualotto AC, Zavascki AP.

J Antimicrob Chemother. 2014 Jun;69(6):1681-7. doi: 10.1093/jac/dku001. Epub 2014 Jan 27.

PMID:
24474430
49.

Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.

Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP.

Int J Antimicrob Agents. 2014 Apr;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002. Epub 2013 Dec 15.

PMID:
24439066
50.

Current status of Pseudomonas aeruginosa vaccine.

Michelim L, Medeiros GS, Zavascki AP.

Curr Pharm Biotechnol. 2013;14(11):951-9. Review.

PMID:
24372247

Supplemental Content

Loading ...
Support Center